Replies to post #225635 on Biotech Values

[n4807g]

Perhaps the time horizon for new trial completion is factored in? Tantalizing data though.

[biotech_researcher]

MRKR - Phase 1 companies, no matter how good the read out, with their inherently low patient count, are uninvestable, imo.